Why Did Array Technologies (ARRY) Stock Fall Over -35% Today?
Array Technologies (ARRY) plunged more than 35% today after its latest earnings report revealed weak profitability and significantly softer 2026 guidance than investors were expecting, despite decent revenue and a strong order book.
Key Takeaways
-
ARRY beat Q4 revenue expectations but showed a sharp year‑over‑year sales decline and a sizeable net loss.
-
Adjusted EBITDA for Q4 badly missed Wall Street estimates, highlighting ongoing margin and cost pressures.
-
2026 guidance for EPS and EBITDA came in well below analyst forecasts, signaling weaker‑than‑hoped earnings power over the next year.
-
The stock had already run up strongly into the print, so the underwhelming outlook triggered a large “sell‑the‑news” and valuation reset.
What Happened in Q4?
Array reported Q4 2025 revenue of about 226 million dollars, roughly 6% above analyst estimates but still almost 18% lower than the same quarter a year ago. Non‑GAAP EPS was essentially breakeven (around 0.01 dollars), only in line with expectations and down from the prior year, while the company posted a net loss of over 160 million dollars to common shareholders.
Adjusted EBITDA for the quarter was roughly 11 million dollars, nearly 30% below Wall Street’s forecast, implying a very thin margin and reinforcing worries that Array is struggling to convert its top line into profits. The quarter confirmed a broader trend: earnings have been falling faster than revenue, with operating margins compressing meaningfully over the last two years.
Why the 2026 Outlook Spooked Investors
For fiscal 2026, management guided to adjusted EPS of about 0.65–0.75 dollars, with the midpoint around 0.70 dollars—more than 20% below the roughly 0.86 dollars analysts were expecting. They also projected EBITDA around 215 million dollars, well under the 250–260 million dollar range many on the Street had penciled in.
This cautious outlook came even as Array highlighted positives like 40% full‑year 2025 revenue growth to roughly 1.28 billion dollars and a record 2.2 billion dollar order book, supported by international expansion and new products. The combination of strong backlog but weaker profitability guidance led investors to conclude that growth is not translating into the level of earnings previously assumed.
Sentiment, Valuation, and Bearish Positioning
The selloff also reflects where sentiment and positioning were before the report. ARRY shares had rallied strongly into February on hopes for a solar recovery and optimism around the company’s growth narrative, with some analysts already warning that revenue and margin expectations looked stretched. Options data had shown notable bearish call activity and growing concern about declining returns on capital, signaling that a downside reaction was likely if the company failed to meaningfully beat and raise.
When the numbers came in—soft EBITDA, cautious EPS guidance, and evidence of ongoing margin pressure—those worries were confirmed, and investors aggressively repriced the stock lower. The result was a drop of more than 35%, as the market reset Array’s valuation to reflect slower earnings growth and execution risk in a still‑choppy utility‑scale solar environment.
Tickeron AI Perspective
Contributor
Momentum Indicator for ARRY turns negative, indicating new downward trend
ARRY saw its Momentum Indicator move below the 0 level on August 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In of the 90 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ARRY entered a downward trend on August 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARRY's RSI Oscillator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ARRY just turned positive on August 03, 2026. Looking at past instances where ARRY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in of 265 cases, the price rose further within the following month. The odds of a continued upward trend are .
ARRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ARRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.432) is normal, around the industry mean (5.838). P/E Ratio (56.911) is within average values for comparable stocks, (116.392). Projected Growth (PEG Ratio) (0.558) is also within normal values, averaging (1.331). ARRY's Dividend Yield (0.000) is considerably lower than the industry average of (0.094). P/S Ratio (0.606) is also within normal values, averaging (6.052).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceutical drugs
Industry AlternativePowerGeneration
Advertisement